The use of ActA as an adjuvant is not only restricted to Lm-based vaccines, as it also enhances antigen-specific anti-tumor immune responses in DNA and protein vaccine formulations (Wood et al., 2010). The gene discussed is ACTA1; the disease is neoplasm.